Vol. 2 No. 12 (2022)
Reimbursement Reviews

Nivolumab (Opdivo)

Published December 23, 2022

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses nivolumab (Opdivo), 240 mg every 2 weeks or 480 mg every 4 weeks, IV administration.
  • Indication: As monotherapy for the adjuvant treatment of adult patients with urothelial carcinoma who are at high risk of recurrence after undergoing radical resection of urothelial carcinoma.